

Amendments to the Claims:

1.-34. (Cancelled)

35. (Currently Amended) A method of ~~treating~~ implanting human intervertebral disc ~~diseases~~ cells into a patient with damaged or diseased intervertebral disc tissue comprising the steps of:

- a) providing a minced human intervertebral disc cells;
- b) culturing said minced human intervertebral cells under conditions to propagate and form a monolayer of human intervertebral disc cells;
- c) isolating the human intervertebral disc cells from said monolayer;
- d) seeding said isolated cells in a carrier such that the isolated cells are dispersed and distributed in the carrier;
- e) culturing said dispersed and distributed cells in said carrier; and
- f) implanting said carrier into a target disc area needing treatment in a human patient.

36. (Cancelled)

37. (Previously Presented) The method according to of Claim 35 wherein said carrier is a member of the group consisting of alginate, agarose, collagen, and mixtures thereof.

38. (Previously Presented) The method according to of Claim 35 wherein at least a portion of said propagated human intervertebral disc cells have re-expressed extracellular matrix materials.

39. (Currently Amended) A method of ~~treating a diseased or injured~~ implanting human intervertebral disc cells into a patient with damaged or diseased intervertebral disc tissue comprising the steps of:

obtaining live human intervertebral ~~human~~ disc cells;

culturing said human intervertebral disc cells under conditions to propagate cultured intervertebral disc cells; and

implanting said cultured human intervertebral disc cells into a target disc area needing treatment in a human patient.

40. (Previously Presented) The method according to Claim 39, wherein said live intervertebral disc cells are obtained from said human patient to be treated.

41. (Currently Amended) The method according to Claim 39, further comprising the step of mincing said live human intervertebral disc cells to obtain an explant prior to culturing.

42. (Previously Presented) The method according to Claim 39, wherein said cultured human intervertebral disc cells are combined with a carrier material.

43. (Previously Presented) The method according to Claim 42, wherein said carrier material is selected from the group consisting of alginate, agarose, collagen, and mixtures thereof.

44. (Previously Presented) The method according to Claim 41, wherein said explant is cultured in the presence of a material selected from the group consisting of fetal calf serum and fetal bovine serum.

45. (Previously Presented) The method according to Claim 41, wherein said explant is cultured in the presence of a material selected from the group consisting of growth factor beta (TGF- β), insulin-like growth factor I, insulin-like growth factor II, basic fibroblast growth factor, acidic fibroblast growth factor, platelet-derived growth factor, insulin, human recombinant bone morphogenetic protein 2, and vitamin D.

46. (Currently Amended) The method according to Claim 39, wherein said implanting step comprises:

debriding diseased or injured disc ~~cells~~ tissue in said patient; and
then delivering said cultured human intervertebral disc cells into the area of debridement.

47. (Currently Amended) The method of Claim 41, further including the steps of:

(a) culturing said explant under conditions to propagate a monolayer of human intervertebral disc cells, wherein said human intervertebral disc cells can be isolated and further propagated upon passaging;

(b) isolating said human intervertebral disc cells from said monolayer to form isolated disc cells;

(c) distributing said isolated human intervertebral disc cells in a carrier material such that said isolated disc cells form a three-dimensional structure; and

(d) culturing said human intervertebral cells in said three-dimensional structure.

48. (Currently Amended) The method according to Claim 47, wherein said live human intervertebral disc cells are obtained from said human patient to be treated.

49. (Previously Presented) The method according to Claim 47, wherein said monolayer of human intervertebral disc cells is combined with a carrier material.

50. (Previously Presented) The method according to Claim 49, wherein said carrier material is selected from the group consisting of alginate, agarose, collagen, and mixtures thereof.

Application No.: 09/560,288

Amendment dated November 5, 2004

Reply to Office action of October 20, 2004

51. (Previously Presented) The method according to Claim 47, wherein said explant is cultured in the presence of a material selected from the group consisting of fetal calf serum and fetal bovine serum.

52-58. (Cancelled)